The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AMPE | +40.91% | N/A | N/A | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +488% |
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.
A positive second-quarter earnings report and anticipation of further details to be discussed this afternoon helped this beaten-down biotech stock recover some previous losses.
Investors liked what they heard in the company's Q4 update.
| Q4 2023 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $1.71M | 0.0% |
| Market Cap / Employee | $0.28M | 0.0% |
| Employees | 6 | 0.0% |
| Net Income | -$2.05M | 0.0% |
| EBITDA | -$2.22M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2023 | YOY Change | |
|---|---|---|
| Net Cash | $4.09M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.27M | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Return On Assets | -89.34% | 0.0% |
| Return On Invested Capital | 37.63% | 0.0% |
| Q4 2023 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.31M | 0.0% |
| Operating Free Cash Flow | -$2.31M | 0.0% |
| Metric | Q4 2023 | YoY Change |
|---|---|---|
| Price to Book | 0.31 | - |
| Price to Tangible Book Value | 0.31 | - |
| Enterprise Value to EBITDA | 0.95 | - |
| Return on Equity | -114.0% | - |
| Total Debt | $0.27M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
